Literature DB >> 20371840

Immune interference of bacteriophage efficacy when treating colibacillosis in poultry.

W E Huff1, G R Huff, N C Rath, A M Donoghue.   

Abstract

A study was conducted to determine if prior exposure with bacteriophage would limit the ability of the same bacteriophage to treat colibacillosis. There were 5 treatments with 3 replicate pens of 20 birds per pen. The treatments consisted of 1) control, 2) birds treated with bacteriophage at 10 and 17 d of age, 3) birds challenged with Escherichia coli at 17 d of age, 4) birds challenged with E. coli and treated with bacteriophage at 17 d of age, and 5) birds treated with bacteriophage at 10 d of age and challenged with E. coli and treated with bacteriophage at 17 d of age. Colibacillosis was induced by injecting 0.1 mL of E. coli into the thoracic airsac containing 1 x 10(6) cfu. The bacteriophage was administered by i.m. injection of 0.1 mL into the thigh, providing a dose of 6.8 x 10(8) pfu. The study was concluded 14 d after E. coli challenge. Mortality in the birds challenged with E. coli and not treated with bacteriophage was 55% (treatment 3), and bacteriophage therapy significantly (P < or = 0.05) reduced mortality to 8% (treatment 4), which was not significantly (P < or = 0.05) different from the 2 non-E. coli-challenged controls (3%, treatment 1, and 2%, treatment 2). However, mortality in the birds administered bacteriophage before challenge with E. coli and treated with bacteriophage (treatment 5) was 33%, which was not significantly different (P < or = 0.05) from the birds that were challenged with E. coli and untreated (55%, treatment 3). A kinetic in vitro assay of bacteriophage activity found that serum from birds pretreated with bacteriophage (treatment 5) inhibited bacteriophage activity. The IgG levels to the bacteriophage in serum from birds pretreated with bacteriophage (treatment 2) were significantly higher at all dilutions compared with control serum (treatment 1). These data demonstrate that prior exposure to bacteriophage will limit bacteriophage therapeutic efficacy and suggests that the reduced efficacy is due to an immune response to bacteriophage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371840     DOI: 10.3382/ps.2009-00528

Source DB:  PubMed          Journal:  Poult Sci        ISSN: 0032-5791            Impact factor:   3.352


  10 in total

Review 1.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

2.  Natural and Induced Antibodies Against Phages in Humans: Induction Kinetics and Immunogenicity for Structural Proteins of PB1-Related Phages.

Authors:  Katarzyna Hodyra-Stefaniak; Zuzanna Kaźmierczak; Joanna Majewska; Sanna Sillankorva; Paulina Miernikiewicz; Ryszard Międzybrodzki; Andrzej Górski; Joana Azeredo; Rob Lavigne; Dorota Lecion; Sylwia Nowak; Marek Harhala; Patryk Waśko; Barbara Owczarek; Katarzyna Gembara; Krystyna Dąbrowska
Journal:  Phage (New Rochelle)       Date:  2020-06-16

3.  Phage Therapy Is Effective in a Mouse Model of Bacterial Equine Keratitis.

Authors:  Takaaki Furusawa; Hidetomo Iwano; Yutaro Hiyashimizu; Kazuki Matsubara; Hidetoshi Higuchi; Hajime Nagahata; Hidekazu Niwa; Yoshinari Katayama; Yuta Kinoshita; Katsuro Hagiwara; Tomohito Iwasaki; Yasunori Tanji; Hiroshi Yokota; Yutaka Tamura
Journal:  Appl Environ Microbiol       Date:  2016-08-15       Impact factor: 4.792

Review 4.  Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review.

Authors:  Krystyna Dąbrowska
Journal:  Med Res Rev       Date:  2019-03-19       Impact factor: 12.944

5.  Bacteriophages engineered to display foreign peptides may become short-circulating phages.

Authors:  Katarzyna Hodyra-Stefaniak; Karolina Lahutta; Joanna Majewska; Zuzanna Kaźmierczak; Dorota Lecion; Marek Harhala; Weronika Kęska; Barbara Owczarek; Ewa Jończyk-Matysiak; Anna Kłopot; Paulina Miernikiewicz; Dominika Kula; Andrzej Górski; Krystyna Dąbrowska
Journal:  Microb Biotechnol       Date:  2019-04-29       Impact factor: 5.813

Review 6.  The Use of Bacteriophages in the Poultry Industry.

Authors:  Katarzyna Żbikowska; Monika Michalczuk; Beata Dolka
Journal:  Animals (Basel)       Date:  2020-05-18       Impact factor: 2.752

7.  Induction of Phage-Specific Antibodies by Two Therapeutic Staphylococcal Bacteriophages Administered per os.

Authors:  Joanna Majewska; Zuzanna Kaźmierczak; Karolina Lahutta; Dorota Lecion; Aleksander Szymczak; Paulina Miernikiewicz; Jarosław Drapała; Marek Harhala; Karolina Marek-Bukowiec; Natalia Jędruchniewicz; Barbara Owczarek; Andrzej Górski; Krystyna Dąbrowska
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

Review 8.  Animal Models of Phage Therapy.

Authors:  Samuel Penziner; Robert T Schooley; David T Pride
Journal:  Front Microbiol       Date:  2021-01-28       Impact factor: 5.640

9.  Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus.

Authors:  Amy E Kirby
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood.

Authors:  Joanna Majewska; Weronika Beta; Dorota Lecion; Katarzyna Hodyra-Stefaniak; Anna Kłopot; Zuzanna Kaźmierczak; Paulina Miernikiewicz; Agnieszka Piotrowicz; Jarosław Ciekot; Barbara Owczarek; Agnieszka Kopciuch; Karolina Wojtyna; Marek Harhala; Mateusz Mąkosa; Krystyna Dąbrowska
Journal:  Viruses       Date:  2015-08-20       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.